ETROPAL AD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.4 BGN | -2.22% |
|
-.--% | -4.35% |
| 02-29 | Etropal AD Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 2023 | Etropal AD Reports Earnings Results for the Nine Months Ended September 30, 2023 | CI |
| Sales 2022 | 6.75M 3.72M 298M | Sales 2023 | 11.2M 6.17M 494M | Capitalization | 23M 12.68M 1.02B |
|---|---|---|---|---|---|
| Net income 2022 | - 0 0 | Net income 2023 | - 0 0 | EV / Sales 2022 | 5.32 x |
| Net Debt 2022 | 4.9M 2.7M 217M | Net Debt 2023 | 4.08M 2.25M 180M | EV / Sales 2023 | 2.42 x |
| P/E ratio 2022 |
-60.7
x | P/E ratio 2023 |
-129
x | Employees | 96 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 48.99% |
More Fundamentals
* Assessed data
More news
| 1 day | -2.22% | ||
| 1 month | -2.22% | ||
| 6 months | -8.33% | ||
| Current year | -4.35% |
1 month
4.40
4.40
Current year
4.004.60
1 year
4.005.80
3 years
4.006.80
5 years
4.006.80
10 years
1.006.80
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 31/12/97 | |
Milena Stoyanova
IRC | Investor Relations Contact | - | - |
Rosica Pencheva
AUD | Comptroller/Controller/Auditor | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 31/12/97 | |
| Director/Board Member | - | 31/12/06 | |
Ivan Petkov
CHM | Chairman | - | 03/12/14 |
Etropal AD is a Bulgaria-based company, which specializes in the scientific research, experimental and development activities in the field of orthopedics and traumatology. The Company manufactures and offers endoprothesys and implants, special bioceramic materials and alloys for the medicine, special surgical instruments, osteosynthesys means, single use syringes, haemodialysis apparatuses and lines and single use medical materials. The Companyâs product portfolio includes fiber dialyzers, arterial and venous lines for haemodialysis, transfusion and infusion sets, fistula and injection needles, catheters, tubes, and femoral implants, among others. The Company operates through one subsidiary, Etropal Trade OOD. As of December 31, 2011, the Companyâs major shareholder was Sintetika AD with a stake of 66.53%.
| 1st Jan change | Capi. | |
|---|---|---|
| -4.35% | 12.11M | |
| +9.48% | 27.43B | |
| -28.65% | 3.18B | |
| -16.08% | 2.53B | |
| +19.05% | 2.49B | |
| +11.11% | 2.16B | |
| -4.24% | 2.03B | |
| +5.56% | 1.61B | |
| +1.69% | 1.31B | |
| +29.73% | 1.29B |
- Stock Market
- Equities
- ETR Stock
